Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
| Website: | www.arrowheadpharma.com |
| Email: | ir@arrowheadpharma.com |
| Main Phone: | +1 626 304-3400 |
| Address: | 225 South Lake Avenue |
| Address 2: | Suite 1050 |
| State: | CA |
| City / Town: | Pasadena |
| Country: | USA |
| Postal Code: | 91101 |
| Exchange: | NGS |
| CEO: | Christopher Anzalone |
| Employees: | 95 |
| NAICS: | Research and Development in Biotechnology (except Nanobiotechnology)(541714) |
We examine several stocks from a technical angle.
Is Abercrombie & Fitch breaking out?
A few names to know.
Spring Bank Pharmaceuticals (SBPH) is hitting clinical milestones in its search for a cure to hepatitis B virus, which affects 325 million people worldwide. (Image source: OnHealth)
Shares of Small-Cap Star Arrowhead Research Corp. (ARWR) are up sharply on Tuesday, with gains in excess of 15% in early trading. The move comes without any clear news item motivating the gains
The biotech bull market is not over. That's the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will
You may not have thought to look northward for biotech innovators, but Bloom Burton & Co. cofounder and President Brian Bloom can show you some truly hot Canadian companies with compelling
Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular
Starting a new investment company and investing in very small biotechs can be a minefield. Because the business is fraught with bad science and liquidity traps, it takes insight and industry
Shares of small-cap biopharmaceutical company Arrowhead Research (ARWR) plunged more than 15 percent Monday on mysteriously negative trading. Arrowhead actually gapped up slightly to begin the
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
| Website: | www.arrowheadpharma.com |
| Email: | ir@arrowheadpharma.com |
| Main Phone: | +1 626 304-3400 |
| Address: | 225 South Lake Avenue |
| Address 2: | Suite 1050 |
| State: | CA |
| City / Town: | Pasadena |
| Country: | USA |
| Postal Code: | 91101 |
| Exchange: | NGS |
| CEO: | Christopher Anzalone |
| Employees: | 95 |
| NAICS: | Research and Development in Biotechnology (except Nanobiotechnology)(541714) |
We examine several stocks from a technical angle.
Is Abercrombie & Fitch breaking out?
A few names to know.
Spring Bank Pharmaceuticals (SBPH) is hitting clinical milestones in its search for a cure to hepatitis B virus, which affects 325 million people worldwide. (Image source: OnHealth)
Shares of Small-Cap Star Arrowhead Research Corp. (ARWR) are up sharply on Tuesday, with gains in excess of 15% in early trading. The move comes without any clear news item motivating the gains
The biotech bull market is not over. That's the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will
You may not have thought to look northward for biotech innovators, but Bloom Burton & Co. cofounder and President Brian Bloom can show you some truly hot Canadian companies with compelling
Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular
Starting a new investment company and investing in very small biotechs can be a minefield. Because the business is fraught with bad science and liquidity traps, it takes insight and industry
Shares of small-cap biopharmaceutical company Arrowhead Research (ARWR) plunged more than 15 percent Monday on mysteriously negative trading. Arrowhead actually gapped up slightly to begin the
| Last Price 36.50 | Change $ 0.55 | Change % 1.53 | Tick N/A |
| Bid 35.56 | Bid Size 100.00 | Ask 37.17 | Ask Size 100.00 |
| Open 36.37 | High 36.89 | Low 35.03 | Prev Close 35.95 |
| Last Trade | Volume 1.4 mi | 52 Wk Hi 38.75 | 52 Wk Low 10.41 |
| Market Cap 3.5 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 95,300,992.00 | EPS (TTM) 0.46 | PE Ratio 74.40 | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 5 | 19 |
| Number of Buys | 1 | 10 |
| Number of Sells | 4 | 9 |
| Net Activity | -151000 | 560792 |
| Last 10 Buys | Shares |
|---|---|
| Christopher Anzalone | 1,000 |
| Christopher Anzalone | 1,000 |
| Mauro Ferrari | 1,000 |
| Mauro Ferrari | 1,000 |
| Christopher Anzalone | 1,000 |
| Kenneth Myszkowski | 1,000 |
| Christopher Anzalone | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Douglas B. Given | 1,000 |
| Kenneth Myszkowski | 1,000 |
| Christopher Anzalone | 1,000 |
| Christopher Anzalone | 1,000 |
| Christopher Anzalone | 1,000 |
| Christopher Anzalone | 1,000 |
| Bruce D. Given | 1,000 |
| Bruce D. Given | 1,000 |
| Douglas B. Given | 1,000 |
| Kenneth Myszkowski | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 15 | 15 | 15 | 15 |
| Low Target Price Estimate | 4.5 | 4.5 | 4.5 | 4.5 |
| Mean Target Price Estimate | 10.5 | 10.5 | 10.08 | 10.5 |
| Standard Deviation | 3.58 | 3.58 | 3.85 | 3.58 |
| Date of Most Recent Estimate | 05/22/18 | 05/22/18 | 05/22/18 | 05/22/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-01 |
| SC 13G | Statement of beneficial ownership of common stock by certain persons | 10 | 2018-05-14 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 36 | 2018-05-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 7 | 2018-05-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-04-25 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-03-27 |
| UPLOAD | Correspondence from the SEC to the Filer | 1 | 2018-03-26 |
| S-8 | Securities offered to employees under employee benefit plans | 9 | 2018-03-22 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-03-20 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-03-16 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 2 | 2 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.33 | 1.33 | 1.67 | 1.8 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait